Cellyan Biotechnology (HKPD) Debt Ratio (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Debt Ratio came in at 0.17 in Q3 2025, up 635.58% year-on-year from 0.02 in Q3 2024, and up 8.6% on a QoQ basis from 0.16 in Q1 2025.
Cellyan Biotechnology (HKPD) Debt Ratio (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Debt Ratio data on file, last reported at 0.17 in Q3 2025.
- On a quarterly basis, Debt Ratio rose 635.58% year-over-year to 0.17 in Q3 2025; TTM through Sep 2025 was 0.17, a 635.58% increase from a year earlier, with the FY2025 full-year figure at 0.16, up 6.58% from the prior year.
- Debt Ratio for Q3 2025 stood at 0.17, up from 0.16 in the prior quarter.
- Over the last five years, Debt Ratio for HKPD reached as high as 0.17 in Q3 2025 and fell as low as 0.02 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn | 0.08 |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn | 0.15 |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn | 0.16 |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn | 0.30 |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - | 0.00 |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn | 0.09 |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn | 0.87 |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn | 0.26 |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 | - |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - | 0.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.17 |
| Mar 31, 2025 | 0.16 |
| Sep 30, 2024 | 0.02 |
| Mar 31, 2024 | 0.15 |